New Haven Pharmaceuticals gets $1.5M investment; Drug-eluting stents safe and effective;

> Second-generation drug-eluting stents are safe and effective in the treatment of left main coronary artery lesions, according to results at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Press release

> Oral controlled release company New Haven Pharmaceuticals has received a $1.5M investment from Connecticut Innovations as part of a $6.6M Series A funding round. Press release

> Drug-eluting balloons are as effective as drug-eluting stents in opening up restenosed arteries. Article

> The U.S. FDA has accepted Ferring Pharmaceuticals' filing of an NDA for its controlled release misoprostol vaginal insert, used in childbirth. Press release

And Finally... Drug-coated stents may have benefits over bare metal stents in patients over 80. Article

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.